All News
ACR20 - Opening Day Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews.
Read Article
ACR20 – Day 1 Report
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Read Article
What is Tony Fauci's greatest achievement?
#ACR20 #LTF @RheumNow
David Liew drdavidliew ( View Tweet)
Presenting work by @drdj & I showing "Risk Factors for Lumbar Vertebral #Osteoporosis Do Not Reflect Factors Traditionally Associated with Osteoporosis at the Hip."
🗓️Session: #Epidemiology & #PublicHealth Posters II
⏰1400 GMT/ 0900 ET today!
🗒️Abs#0544
#DEXA #ACR20 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Ground-breaking news... the end of #glucocorticoid use in #AAV?
very exciting to reduce GC toxicity! https://t.co/43eCofpOIX
KenWarringtonMD MdWarrington ( View Tweet)
Is it Relapsing #Polychondritis or VEXAS - RP?
Data from @maferradastrong @petercgrayson tell how to tease them apart: #ACR20 #RheumTwitter https://t.co/NwfbqjX5Kw
KenWarringtonMD MdWarrington ( View Tweet)
Use of diagnostic imaging for #GCA is ⬆️
Use of temporal artery biopsy⬇️
data from #MayoClinicRheumatology @garveythomasma1
#acr20 #RheumTwitter https://t.co/kQTg5FTlVq
KenWarringtonMD MdWarrington ( View Tweet)
HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20
https://t.co/zPIaFIiqr5 https://t.co/Wk8YQpIpo7
Links:
Dr. John Cush RheumNow ( View Tweet)
Great talk #ACR20 @anisha_dua re:monitoring in GCA/TAK
Remember different distributions in GCA/TAK
Slick summary slides with pros/cons of each modality
I find myself picking based on clinical context, suspected involvement/extent, and availability
#ACRambassador https://t.co/euMGbwirG9
Mike Putman EBRheum ( View Tweet)
Talk on collaborative research and team building by @rheum_covid leaders @JYazdanyMD & @philipcrobinson
Dr. Yazdany with an illustration of what the journey might look like for the ECI phase & beyond
#ACR20 #ACRambassador https://t.co/ISNQSrFWws
Rheum Cat rheum_cat ( View Tweet)
SELECT-PsA2 group refractory to prior bDMARD therapy
UPA - useful oral JAKi option in Psoriatic Arthritis
Safety consistent with what we know from RA. More Sfx at 30mg. No clear VTE signal
#ACR20 https://t.co/XpprRprugI
Dr Irwin Lim _connectedcare ( View Tweet)
Cohort study of 186 AI patients from New York => Among patients hospitalized with COVID-19, individuals with autoimmune disease did not have an increased risk of a composite outcome of intensive care unit admission, intubation, or death.
https://t.co/EXGyfrHnjH @jrheum
Dr Philip Robinson philipcrobinson ( View Tweet)
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies https://t.co/itrgSeNted #RA #prednisone 18-30% flare ceasing Pred - imi for bridging rather than commence oral! Eular guidelines have a lot to answer for
Peter Nash drpnash ( View Tweet)
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years https://t.co/9YNEGXKoAD #RA #filgotinib low vte & low zoster rates
Peter Nash drpnash ( View Tweet)
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis https://t.co/T3cXYlCSRC #RA #Upadacitinib 3 yr safety data
Peter Nash drpnash ( View Tweet)
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms https://t.co/sLGxMwJUhk #SLE #fatigue - fatigue remains a big problem
Peter Nash drpnash ( View Tweet)
Tender non-swollen joints NOT associated with #ultrasound synovitis in DMARD-naïve early #PsoriaticArthritis
👉🏽https://t.co/XcuhlZbpSV
by Dr Dubash @LeedsTeamSpA @LeedsBRC
#ACR20 #0313 https://t.co/TbpxIy83Qt
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report https://t.co/zdpk6IvxP0 #PsA # predictors
Peter Nash drpnash ( View Tweet)
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis https://t.co/hgPDtFRxer #PsA #Guselkumab
Peter Nash drpnash ( View Tweet)
